Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Ascentage Pharma Receives Clearance from US FDA to Proceed with Phase III Clinical Trial for Lisaftoclax (APG-2575)

Monday, August 07, 2023

Ascentage Pharma has received clearance from the US Food and Drug Administration (FDA) to initiate a global Phase III study for their novel Bcl-2 inhibitor, lisaftoclax (APG-2575), in the treatment of patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi).

The Phase III study, named APG2575CG301, is a significant step in the development of lisaftoclax as a potential treatment option for CLL/SLL patients who have relapsed or developed resistance to existing therapies, including BTKis.

The study is designed as a randomised-controlled trial and will be conducted across multiple centres globally. Its main focus will be to evaluate the efficacy and safety of combining lisaftoclax with a BTKi in this specific patient population.

Lisaftoclax is an orally administered small-molecule Bcl-2 selective inhibitor. Bcl-2 is a protein that plays a crucial role in regulating apoptosis, the process of programmed cell death. In cancer cells, overexpression of Bcl-2 can disrupt normal apoptosis and contribute to uncontrolled cell growth and survival. By targeting Bcl-2, lisaftoclax aims to restore the normal apoptotic process, leading to the elimination of cancer cells.

CLL/SLL is a type of leukaemia that predominantly affects adults. It is characterised by the abnormal accumulation of mature lymphocytes in the blood, bone marrow, and lymph nodes. Although current treatment options, such as immunotherapies, chemotherapies, and BTKis, can initially lead to positive responses in patients, relapse and drug resistance often emerge as significant challenges in managing the disease.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024